Skip to main content
Premium Trial:

Request an Annual Quote

Out in the Light

During the first six months of 2009, Pfizer paid about $20 million to some 4,500 medical professionals in consulting and speaking fees, reports the New York Times. In addition, Pfizer paid $15.3 million to 250 academic medical centers for clinical trials. These details were released as part of an agreement Pfizer made with the US government during an investigation into the company's promotion of drugs for off-label uses. Eli Lilly, Merck, and GlaxoSmithKline have made similar disclosures. Pfizer, NPR's Shots blog points out, was the only company thus far to release this information as a database, which may be found here. The Times adds that as part of the health care reform bill, beginning in 2012, all drug and device makers will have to disclose payments to doctors that exceed $10.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.